<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515551</url>
  </required_header>
  <id_info>
    <org_study_id>IMCnyeso-101</org_study_id>
    <nct_id>NCT03515551</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers</brief_title>
  <official_title>A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunocore Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMCnyeso is a new biological therapy designed for the treatment of cancers which express&#xD;
      NY-ESO-1 and/or LAGE-1A. This is a first-in-human trial designed to evaluate the safety and&#xD;
      efficacy of IMCnyeso in adult patients who have the appropriate HLA-A2 tissue marker and&#xD;
      whose cancer is positive for NY-ESO-1 and/or LAGE-A1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open label, dose finding Phase 1/2 study of single agent IMCnyeso&#xD;
      administered in patients with NY-ESO-1 and/or LAGE-A1 positive tumors. The primary objective&#xD;
      of the dose escalation phase (Arm 1) is to determine the maximum tolerated dose (MTD) and/or&#xD;
      recommended Phase II dose (RP2D) of IMCnyeso in patients with advanced solid tumors.&#xD;
      Preliminary efficacy will be evaluated in Arm 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Strategic decision to stop development and not based on any safety concerns&#xD;
  </why_stopped>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">May 10, 2021</completion_date>
  <primary_completion_date type="Actual">May 10, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Incidence of dose-limiting toxicities (DLT)</measure>
    <time_frame>from first dose to end of DLT period (up until Day 28 after first dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: incidence and severity of adverse events (AE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in body temperature</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Body temperature will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in pulse</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Pulse will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in respiratory rate</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Respiratory rate will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in blood pressure</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Blood pressure will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated up to 1 year)</time_frame>
    <description>Tolerability of study treatment will be assessed by summarizing the number of treatment dose interruptions and dose reductions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: incidence and severity of adverse events (AE)</measure>
    <time_frame>first dose to 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in body temperature</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Body temperature will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in pulse</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Pulse will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in respiratory rate</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Respiratory rate will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in blood pressure</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Blood pressure will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>first dose through last dose (anticipated up to 1 year)</time_frame>
    <description>Tolerability of study treatment will be assessed by summarizing the number of treatment dose interruptions and dose reductions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The maximum observed plasma drug concentration after single dose administration (Cmax)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The elimination half-life (t1/2)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity the incidence of anti-IMCnyeso antibody formation Immunogenicity the incidence of anti-IMCnyeso antibody formation</measure>
    <time_frame>6-12 months (AUC will be assessed monthly for 6-12 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Select Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMCnyeso dose Escalation Phase with approximately 4-10 cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase (Arm 1) n=approximately 27 patients to establish the MTD/RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMCnyeso expansion with 3 cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=9-24/cohort treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMCnyeso</intervention_name>
    <description>Weekly IV infusions of IMCnyeso</description>
    <arm_group_label>IMCnyeso dose Escalation Phase with approximately 4-10 cohorts</arm_group_label>
    <arm_group_label>IMCnyeso expansion with 3 cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HLA-A*0201 positive&#xD;
&#xD;
          2. NY-ESO-1 and/or LAGE-1A positive tumor&#xD;
&#xD;
          3. ECOG PS 0 or 1&#xD;
&#xD;
          4. Selected advanced solid tumors&#xD;
&#xD;
          5. Relapsed from, refractory to, or intolerant of standard therapy&#xD;
&#xD;
          6. Measurable disease per RECIST v1.1&#xD;
&#xD;
          7. If applicable, must agree to use highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic or untreated central nervous system metastasis&#xD;
&#xD;
          2. Inadequate washout from prior anticancer therapy&#xD;
&#xD;
          3. Significant ongoing toxicity from prior anticancer treatment&#xD;
&#xD;
          4. Impaired baseline organ function as evaluated by out-of-range laboratory values&#xD;
&#xD;
          5. Clinically significant cardiac disease&#xD;
&#xD;
          6. Active infection requiring systemic antibiotic therapy&#xD;
&#xD;
          7. Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
          9. Ongoing treatment with systemic steroids or other immunosuppressive therapies&#xD;
&#xD;
         10. Significant secondary malignancy&#xD;
&#xD;
         11. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaad Abdullah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Immunocore Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology NASH - SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMCnyeso</keyword>
  <keyword>Immunotherapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

